Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
91. |
ECCT/16/10/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Professor Walter Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Research (Nairobi City county) 2. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) |
View |
92. |
ECCT/16/08/03 | IMPAACT 2001 A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed project |
View |
93. |
ECCT/16/07/05 | HESTIA 1 Multicentre, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled 4 weeks extension phase in paediatric patients with sickle cell disease |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Videlis Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. Gertrude’s Children’s Hospital (Nairobi City county) 2. Kemri CRDR research center at Chandaria Health Centre Dagoretti (Nairobi City county) 3. Clinical Research Annex at the Siaya County Referral Hospital (Siaya county) 4. Kondele Children’s Hospital, KEMRI – Centre for Clinical Research (Kisumu county) |
View |
94. |
ECCT/16/06/01 | P1115 Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study |
Principal Investigator(s) 1. Fredrick Sawe Site(s) in Kenya KEMRI WALTER REED PROJECT KERICHO |
View |
95. |
ECCT/16/05/01 | A5338 A5338 An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) |
Principal Investigator(s) 1. David Schnabel Site(s) in Kenya KISUMU CRS |
View |